First-line treatment with polatuzumab vedotin improves efficacy and survival in newly diagnosed patients with advanced diffuse large B-cell lymphoma: a multicentre retrospective analysis. [PDF]
Bai SJ +11 more
europepmc +1 more source
Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang +9 more
wiley +1 more source
Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor as a support for chemotherapy for gestational trophoblastic neoplasia: a propensity score matching analysis. [PDF]
Zhao X +5 more
europepmc +1 more source
A RATIONAL APPROACH TO THE PROBLEM OF CANCER CHEMOTHERAPY
L. V. Heilbrunn, Walter L. Wilson
openalex +2 more sources
Metal Nanoclusters for Cancer Imaging and Treatment
This review aims to provide a comprehensive summary and discussion of the core–shell design capabilities of metal nanoclusters (NCs) at the atomic level for cancer imaging and treatment. It offers essential insights into the design principles of metal NCs while also encouraging the exploration of other nanomaterials and their potential theranostic ...
Haiguang Zhu +5 more
wiley +1 more source
Sugemalimab plus chemotherapy versus chemotherapy for advanced gastric cancer in China: a cost-effectiveness analysis. [PDF]
Lin X, Zhu H, Zheng Z.
europepmc +1 more source
Many known diseases arise from dysregulated gene expression, and differentially expressed genes can serve as biomarkers to distinguish diseased cells from healthy tissues. In this study, reconfigurable nucleic acid nanoparticles (recNANPs) are introduced that can detect overexpressed cancer biomarkers and subsequently release RNAi inducers to silence ...
Yelixza I. Avila +7 more
wiley +1 more source
Impact of adjuvant chemotherapy delay on overall survival in early-stage breast cancer: a retrospective analysis. [PDF]
Alhalabi A +5 more
europepmc +1 more source
Zr‐Fe MOF@Ribociclib@Herceptin (ZFRH) efficiently targets/kills Human Epidermal Growth Factor Receptor 2/Estrogen Receptor‐positive (HER2/ER+) breast cancer cells. It combats tumors by: 1) Elevating ROS, altering redox balance; 2) Inhibiting transcription; 3) Inducing pyroptosis.
Hongkun Miao +8 more
wiley +1 more source

